Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia

Farrukh Awan, MD, MS, Ulrich Jaeger, MD, Robert Rifkin, MD, Michael J Thirman, MD, John C. Byrd, MD, Michael Hallek, MD, Scott Stromatt, MD, John M. Pagel, MD, PhD

Blood (2012) 120 (21): 1795.

https://doi.org/10.1182/blood.V120.21.1795.1795

Published: 2012

Journal Articles

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Sarit Assouline, Julie E. Chang, MD, Bruce D. Cheson, MD, Robert Rifkin, MD, Solomon Hamburg, MD, PhD, Ruben Reyes, MD, Ai-Min Hui, MD, PhD, Jiang Yu, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Yaping Shou, Peter Martin, MD

Blood (2012) 120 (21): 3646.

https://doi.org/10.1182/blood.V120.21.3646.3646

Published: 2012

Journal Articles

MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study

Sarit Assouline, MD, Julie Chang, MD, Robert Rifkin, MD, Ai-Min Hui, MD, Deborah Berg, RN, MSN, Neeraj Gupta, PhD, Yingmei Xi, PhD, Alessandra Di Bacco, PhD, Peter Martin, MD

Blood (2011) 118 (21): 2672.

https://doi.org/10.1182/blood.V118.21.2672.2672

Published: 2011

Journal Articles

A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),

Bipin Mistry, Ph.D., Mark M Jones, MD, Peter Kubiak, Ph.D., Guillermo Garcia-Manero, Mark R. Litzow, MD, Ruben A. Mesa, MD, Robert Rifkin, MD, Peter Tarassoff, MD, Ph.D., Jorge E. Cortes

Blood (2011) 118 (21): 3801.

https://doi.org/10.1182/blood.V118.21.3801.3801

Published: 2011

Journal Articles

Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients

Chris L. Pashos, PhD, Brian GM Durie, MD, Robert Rifkin, MD, Howard Terebelo, DO, Cristina Gasparetto, MD, Jayesh Mehta, MD, Kathleen Toomey, MD, Rafat Abonour, MD, Rafael Fonseca, MD, Mohit Narang, MD, Jatin J Shah, MD, Arlene S Swern, PhD, Kristen A Sullivan, MBA, Thomas K. Street, RPh, Zeba M. Khan, PhD

Blood (2011) 118 (21): 5070.

https://doi.org/10.1182/blood.V118.21.5070.5070

Published: 2011

Journal Articles

Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage

Blood (2011) 118 (21): 3150.

https://doi.org/10.1182/blood.V118.21.3150.3150

Published: 2011

Journal Articles

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Hui Huang, PhD, MBA, Sanggyu Choi, PhD, Deyanira Corzo, MD

Blood (2011) 118 (21): 1864.

https://doi.org/10.1182/blood.V118.21.1864.1864

Published: 2011

Journal Articles

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Ruben Niesvizky, MD, Ian W. Flinn, MD, PhD, Robert Rifkin, MD, Nashat Gabrail, MD, Veena Charu, MD, Billy Clowney, MD, James Essell, MD, Yousuf Gaffar, MD, Thomas A. Warr, MD, FACP, Rachel Neuwirth, MS, Deyanira Corzo, MD, James Reeves, MD

Blood (2011) 118 (21): 478.

https://doi.org/10.1182/blood.V118.21.478.478

Published: 2011

Journal Articles

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Robert Rifkin, MD, Roy Beveridge, MD, Gary Spitzer, MD, Gregory Orloff, MD, Romeo Mandanas, MD, Dean McGaughey, MD, Mark Brunvand, MD, Feng Zhan, PhD, Kristi A. Boehm, MS, Lina Asmar, PhD

Blood (2007) 110 (11): 4936.

https://doi.org/10.1182/blood.V110.11.4936.4936

Published: 2007

Journal Articles

Preliminary Data on Once-Daily IV Busulfan at 3.2 mg/kg/day Indicate That It Is Safe as a Component of the Conditioning Regimen for Hematopoietic Stem Cell Transplantation.

Mark W. Brunvand, MD, Robert Rifkin, MD, Jeffry V. Matous, MD, Peter McSweeney, MD, Scott Bearman, MD

Blood (2004) 104 (11): 5033.

https://doi.org/10.1182/blood.V104.11.5033.5033

Published: 2004

NARROW

Phase 1b Study of TRU-016, an Anti-CD37 SMIP™ Protein, in Combination with Bendamustine Vs Bendamustine Alone in Relapsed Chronic Lymphocytic Leukemia

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study

A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS),

Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients

Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage

Patient-Reported Quality of Life (QoL) in Elderly, Newly Diagnosed Multiple Myeloma (MM) Patients Receiving Bortezomib-Based Combinations: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results From All Randomized Patients in the Community-Based, Phase 3b UPFRONT Study

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Preliminary Data on Once-Daily IV Busulfan at 3.2 mg/kg/day Indicate That It Is Safe as a Component of the Conditioning Regimen for Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only